INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026

INOVIO PHARMACEUTICALS, INC.

2026-Q2 EPS reported -$0.34

Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.
Cash and investments $36.7M at June 30, 2026, plus $18.3M from July offering; runway into late Q1 2027.
FDA review of INO-3107 BLA continues; PDUFA target action date October 30, 2026; commercial launch prep ongoing.
ApolloBio reported positive Phase 3 topline for VGX-3100 in China for cervical dysplasia.
Operating expenses fell to $18.6M from $23.1M YoY; R&D down to $10.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.